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BACKGROUND: There is a continued high prevalence of
benzodiazepine use by older community-residing adults
and of their continued prescription by practitioners,
despite well known adverse effects and the availability
of safer, effective alternatives.
OBJECTIVES: To understand factors influencing
chronic use of benzodiazepines in older adults.
DESIGN: Qualitative study, semistructured interviews
with physicians.
PARTICIPANTS: Thirty-three practicing primary care
physicians around Philadelphia.
APPROACH: Qualitative interviews were audiotaped,
transcribed, and entered into a qualitative software
program. A multidisciplinary team coded transcripts
and developed themes.
RESULTS: Physicians generally endorsed benzodiaze-
pines as effective treatment for anxiety, citing quick
action and strong patient satisfaction. The use of
benzodiazepines in older adults was not seen to be
problematic because they did not show drug-seeking or
escalating dose behavior suggesting addiction. Physi-
cians minimized other risks of benzodiazepines and did
not view monitoring or restricting renewal of prescrip-
tions as an important clinical focus relative to higher-
priority medical issues. Many physicians expressed
skepticism about risks of continued use and consider-
able pessimism in the successful taper/discontinuation
in older patients with long-term use and prior failed
attempts. Physicians also anticipated patient resistance
to any such efforts, including switching physicians.
CONCLUSIONS: Primary care physicians are averse to
addressing the public health problem of benzodiazepine
overuse in the elderly. Their attitudes generally conflict
with practice guidelines and they complain of a lack of
training in constructive strategies to address this
problem. A 2-pronged effort should focus on increasing
skill level and preventing new cases of benzodiazepine
dependency through improved patient education and
vigilant monitoring of prescription renewal.
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INTRODUCTION
The potential negative side effect profile and toxicity of
benzodiazepines on older adults has been well established.
Problems associated with benzodiazepine use by the elderly
include sleep disturbance, cognitive difficulty, impairment in
activities of daily living, motor vehicle crashes, and gait
concerns (e.g., accidental falls and fall-related fractures).
1–6
Guidelines defining the appropriate use of benzodiazepines
in the elderly recommend prescriptions be intermittent, brief,
and for purposes of acute symptom relief.
7,8 Despite guide-
lines, benzodiazepine use in older adults remains high with a
mean current prevalence of 12.3% (ranging from 9.5% to 20%)
in community-dwelling populations.
9,10 Continuous use is
deemed high and likely reflects unnecessary or suboptimal
treatment.
11,12
As the main prescribers of these drugs, primary care
practitioners are the most likely source of information that
will help understand and eventually solve this public health
problem.
PARTICIPANTS AND METHODS
This study explored possible explanations of chronic use of
benzodiazepines in older adults through qualitative analysis of
in-depth interviews with primary care physicians. Thirty-three
physicians were recruited from the Philadelphia area through
postal mailings, word-of-mouth, and phone solicitations with
deliberate efforts to diversify experience level and practice
setting. A semistructured interview guide was constructed to
explore a wide range of potentially relevant issues, with the
assistance of 2 board-certified geriatric psychiatrists, a medi-
cal anthropologist, and a sociologist.
DATA COLLECTION AND ANALYSIS
Interviews were conducted by an experienced research psy-
chologist specialist in geriatrics and dissemination (JMC) and
audiotaped, face-to-face (n=28) or by telephone (n=5). The
interview first inquired about how the physician conceptual-
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303ized clinical problems of acute life stress, insomnia, anxiety,
and depression in older patients, with specific emphasis on the
role for benzodiazepines. The interviewer then assessed the
typical way in which the physician would, with an elderly
patient, consider prescribing a benzodiazepine; evaluate treat-
ment response and adverse effects; and decide to renew
prescriptions. Finally, physicians were asked about strategies
for identifying and addressing problems with benzodiazepine
use, including the availability and use of psychotherapy as an
alternative. Verbatim transcriptions of interviews were entered
into QSR NVivo (version 2.0) for coding and analysis.
Narrative analysis proceeded systematically in 3 main
steps: generating initial themes through independent study
and rational analysis of transcripts, abstraction and conden-
sation of themes through further discussion to identify
common themes and reconcile conflicting observations, and
creation of summary statements for each theme.
13 Additional
physicians were interviewed until no new concepts were
identified (theoretical saturation). In summary, procedures
used to ensure the internal validity of this qualitative study
include semistandardization of the interview, audiotaping and
professional transcription, standardized data coding, and an
iterative approach to thematic extraction.
RESULTS
Thirty-three physicians (22 men and 11 women) participated.
Mean age was 47; 29 were Caucasian, 3 were East Indian, and
1 was Asian. Practice characteristics were full-time practice
24
or part-time
7; group practice
24 or solo practice
9; suburban
17 or
inner city
16; and family medicine,
18 geriatrics,
10 or general
internists.
5
In general discussion, physicians expressed agreement with
current guidelines identifying benzodiazepines as mainly
appropriate for short-term treatment only, not a stand-alone
treatment for major depressive disorder, and not first-line
treatments for long-term anxiety or chronic insomnia.
Understanding the Disparity Between Beliefs
and Practice
In contrast to stated beliefs about best practice, physicians
estimated that 5–10% of their older adult patients were using
benzodiazepines on a daily basis for at least the past 3 months.
Evidence was found for 3 overarching themes that were
meaningfully distinct, but interrelated (Table 1).
Physician Minimization of the Problem. Virtually no physician
considered benzodiazepine use among the elderly to be a
priority clinical or public health problem. Four recurring
subthemes supporting this conclusion were identified (see the
4 following subsections).
Ia. No Addiction Seen in this Population. An u m b e ro f
physicians appeared to have different rules and strategies for
prescribing these medications in older versus younger adults,
and were more tolerant of long-term use in the elderly.
In younger age groups I’m more suspicious of abuse of it
and sellin’ it.
Once you put them on it it’s very difficult for them to
come off, so as patients get older I become much more
lenient with my prescribing... maybe I can empathize
with them more... they’re now pretty much set in their
ways.
If it looks like it’s close to the end of that person’s life,
you know, why bother... just let them go in peace.
Thus, a primary consideration in the prescription of benzo-
diazepines to older adults was the low potential for abuse and
addiction. This seemed to be framed as a “moral” issue rather
than a clinical question of balancing adverse effects—that is,
the adverse effect of iatrogenic abuse/dependence.
Ib. Little Recognition of Adverse Effects Other than Addiction.
You know, is it... terrible for somebody like that to be on
3 mg of Klonopin a day for the rest of their lives? If it
works and she doesn’t abuse it, who cares?
The potential for adverse health effects other than iatrogenic
addiction were largely minimized or ignored, and guidelines
were criticized as out of touch with real-world problems.
Regardless of whether this perception is accurate, it is likely
a major barrier to addressing the problem.
Ic. Continuation is Compassionate; Discontinuation is Harsh.
Lacking strategies for both successful taper and alternative
treatment, physicians did not want to withhold a medication
that provided ongoing relief to the patient and believed that
reducing or discontinuing benzodiazepines would unnecessarily
cause undue suffering.
Let’s pretend it’s an octogenarian ... if it’s gonna make
the patient feel better, I don’t care if the patient’s on it for
the rest of their life.
You’d like to say, well, I can just put a great big brick wall
in front of me and the patient with benzodiazepines but
it doesn’t work that way... You feel like you’ve gotta give
the patient something to help.
Table 1. Categories Underlying Use of Benzodiazepines in the Elderly
Categories
Physician minimization of benzodiazepine use as a problem
No addiction seen in this population
Little recognition of adverse effects other than addiction
Continuation is compassionate; discontinuation is harsh
Low-priority relative to medical problems
Justification of short- and long-term benzodiazepine use
Effectiveness for anxiety and sleep problems
Belief that stable dosage equals safe and effective
Attempt to discontinue will fail
Anticipated resistance from patients
Cost–benefit: Question patient gain and highlight suffering
involved in taper or discontinuation
Wider organizational factors and system constraints
Limited physician time
Poor reimbursement for mental health care
Older patients limited acceptance and access to mental health
services
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about competing medical management issues that were of
higher priority during relatively brief medical appointments.
The sad fact is their primary care doctors make
choices... there’s almost sort of a running tally going on
in your head when you’re talking to a patient. Do I want
to open this can of worms right now or do I want to deal
with these four other things that are gonna result in a
heart attack if I don’t deal with them, or a stroke. Or do I
want to deal with this other thing that I know is going to
be incredibly time-consuming and difficult, and difficult
to deal with this patient, when I don’t think that the
therapy is really that bad for them.
In the greater scheme of things I have a feeling there are
other problems that are much, much worse.
Justification of Short- and Long-Term Benzodiazepine Use. The
majority of physicians were somewhat vague and reluctant to
describe the circumstances in which they would prescribe
benzodiazepines in new patients. Five related subthemes were
identified (see the 5 following subsections).
IIa. Effectiveness for Anxiety and Sleep Problems. Physicians
emphasized that benzodiazepines are rapidly, highly effective
for anxiety and sleep problems, despite the fact that they are
not first-line treatment for insomnia.
Sometimes it’s the easiest choice for people to feel best
quickly. They feel better fast.
They sometimes feel that the other ones don’t work. I
mean it’s not such an immediate effect... everybody likes
an immediate effect. If you don’t have an immediate
effect then sometimes you feel that it’s not working and
you won’t give it time to work.
IIb. Belief that Stable Dosage Equals Safe and Effective.
Physicians reasoned that a benzodiazepine at a stable dose
for months–years was probably helping and doing no harm.
I don’t push it ‘cause the downside is she seems to
tolerate it fine, it’s not a high dose, it hasn’t escalated
and she finds it beneficial. I’m not worried about fifteen
or twenty years down the road I’m gonna still be giving
her Ativan. She’s not gonna be alive in twenty years
down the road and I’m sort of surprised she’s alive now...
She really needs it. If it helps her get through her days
better, great.
IIc. Attempt to Discontinue will Fail. Almost all of the physicians
noted that they had tried and failed to taper and discontinue
benzodiazepines in some patients. None had a systematic
strategy for addressing patient concerns that inevitably
emerge during this process.
I suggest to them that ideally we should try to get them
off of that, but if they’re saying, been there, done that,
that didn’t work for me when I came off of this, I don’t
think it’s worth getting into a big knock-down drag-out
[fight] with them or having them leave my practice over
this issue.
It is a doctor throwing his hands up in resignation in, oh
my god, she’s been on it for years, I’ll just give her what
she asks for and I won’t have to sit here and explain
things for twenty minutes about why I want to get her
off. ‘Cause it is, it is an effort and time and frustration
trying to get people off of these things. So maybe it’s just
the path of least resistance.
IId. Anticipated Resistance from Patients. Physicians
anticipated resistance in response to even broaching the topic
of taper/discontinuation with an older patient. Prospects
ranged from questioning the doctor’sa u t h o r i t ya n d
competence, to minimization of potential negative side effects,
to finding another doctor who was willing to prescribe it.
Every time I tried to say Lorazepam isn’t the right med-
ication, she said, ‘but I’ve been on it for thirty years.’ I
think they enjoy the effects of the benzodiazepine and
they don’t want to have that taken away. It’s literally like
taking candy from a baby and people that have enjoyed
the effects of that class of drugs don’t wanna give it up. I
can’t lose patients over this.
IIe. Cost-benefit: Question Patient Gain and Highlight Suffering
Involved in Taper or Discontinuation. In the end, physicians
believed the advantages of continuing benzodiazepines in the
elderly outweighed the problems.
You don’t wanna take somebody who is functioning well
and create a situation where they function badly and a
situation where they are sort of utilizing normal health
care resources currently. You know, seeing me intermit-
tently, three, four times a year... being stable with respect
to their relationships, etcetera, and create a situation
where they are calling me every two, three days.
Wider Organizational Factors and System Constraints. Several
physicians expressed frustration that system constraints made
it impossible for them to provide the more comprehensive care
they wanted to give their patients, summarized in 3 subthemes
(see the 3 following subsections).
IIIa. Limited Physician Time. Physicians cited time constraints as
both promoting benzodiazepine use and impeding
discontinuation efforts.
A benzodiazepine becomes a quick fix because you don’t
havetime,thisiswhattheywant,theydon’tfeelgood,here
it is. It numbs them up and you’re not gonna get a phone
call afterwards, you’re not gonna get anything, you’ll see
them in a month, here’s your renewal, see ya later.
It’s just so much easier to just prescribe something and
just walk away.
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for reimbursing treatment of mental health problems in
primary care was frequently mentioned in this context.
Medicare... will not reimburse any internist for a
psychiatric diagnosis.
Reimbursement is very low... I think if it was something
that we did get reimbursed on I think you would see
physicians’ attitudes a lot different. You’db em o r e
willing to spend time.
IIIc. Older Patients Limited Acceptance and Access to Mental
Health Services. Physicians thought their older adult patients
would resist or be unable to pursue mental health referrals for
multiple reasons ranging from stigma to financial and
transportation difficulties.
I think patients in my office are much more ready to
admit the fact that taking this medicine now is cheaper
and simpler and easier and less stigma, nobody knows
about, etcetera and [patients think] I can do that forever
and I would rather do that and keep a lid on things than
have to deal with everything else that’su n d e rt h e
surface in my life and try to sit down with somebody
and talk it out and pay co-pays every time I go to see
somebody. And then finding somebody that can do that,
who I trust and like and it becomes an onerous, tedious,
almost overwhelming task.
DISCUSSION
Physicians were aware of practice guideline recommendations.
However, none believed benzodiazepine use was a serious
clinical problem in older adults, and all believed there were
multiple barriers to addressing use in real-world practice,
including that raising the issue would threaten their alliance
with patients.
Physicians focused almost entirely on “addiction” as the
main concern with benzodiazepine use and discontinuation,
and their reasoning seemed based on moral rather than
scientific criteria, with frequent mention of “drug addicts”
and “drug-seeking behavior.” Most physicians focused on
dependency as an adverse effect to the exclusion of all other
adverse effects, and then evaluated their own prescribing
patterns based on this formula. Herein seems to be another
disparity between guidelines generated by academics and the
actual behavior of community practitioners.
14,15
We found that physicians believed that attempts to reduce
benzodiazepine use in the elderly would threaten their alliance
with these patients. Physicians expressed dissatisfaction
about a lack of preparation to address the issue, reflected in
a lack of concrete strategies. Concerns about patient resis-
tance were thus compounded by physicians’ lack of a sense of
efficacy in addressing the difficult clinical issues that would be
raised if they approached older patients about continuous
benzodiazepine use.
Limitations of the present study include possible selection
bias in the willingness of physicians to be interviewed about a
potentially sensitive topic and possible social desirability and
defensiveness in the responses provided in the interview.
However, physicians were generally forthcoming about the
ways in which their practice patterns differed rather markedly
from guidelines. They quite simply disagreed with them.
Four randomized controlled trials have examined interven-
tions for reducing benzodiazepine use in the United Kingdom
and Canada. The results are equivocal. In a prospective,
randomized, 3-cell clinical trial in and around London,
Heather and colleagues
16 found that long-term users who
received a letter from their physicians suggesting a reduction
in the use of benzodiazepines, and those who received this
letter plus 4 monthly information sheets about dose reduction
and coping without it, significantly reduced their benzodiaze-
pine intake over a treat-as-usual condition.
17 However, anoth-
er British study found no efficacy for a minimal intervention
consisting of advice from a general practitioner and a self-help
booklet versus treatment-as-usual.
18
Over the past 2 decades, physicians in the United Kingdom
have received substantial advice about the problems associated
with prescribing benzodiazepines, and the British national
formulary states that hypnotic drugs should be avoided in
elderly people.
17 In addition, the National Health Service
recommends identifying long-term benzodiazepine users and
planning for discontinuation if possible.
19 In the decentralized
health care system in the United States, organizing systematic
and system-wide programs such as these are extraordinarily
difficult.
In Ontario, Canada, a randomized controlled trial of confi-
dential feedback and educational material to primary care
physicians that aimed to reduce benzodiazepine use in elderly
patients was also ineffective.
20 Virtually all research to date
finds that older adults have increased vulnerability to serious
adverse effects of these drugs.
1–6,11,12 However, simply creating
and disseminating guidelines based on this research is
ineffective in changing practice patterns.
Recent U.S. legislation gives the appearance of addressing
this issue using a rigid economic (rather than educational)
approach. The Centers for Medicare and Medicaid Services
excluded benzodiazepines from coverage in Medicare Part D,
along with a seemingly unrelated list of other medication
categories including barbiturates, medications to promote
weight loss or weight gain, fertility, hair growth, and nonpre-
scription drugs.
21 This set of exclusions was taken verbatim
from the Omnibus Reconciliation Act of 1990, and the
benzodiazepine exclusion seems to have been the result of
lobbying by activist groups, namely, Ralph Nader’s Public
Citizen organization.
22,23 It is notable that all states essentially
overruled this decision by continuing to cover benzodiaze-
pines, with some states adding additional restrictions or
monitoring.
21 In response to the recent Medicare Part D
legislation, numerous professional and patient advocacy orga-
nizations have called for removal of the benzodiazepine
exclusion because it could result in dangerous, abrupt dis-
continuation of benzodiazepines, and obstructs the appropri-
ate use of these medications.
21,24
A 2-track public health strategy could potentially address
the issues we identified in this study. First, because physicians
agreed in principle that short-term treatment with benzodia-
zepines is the best practice, education and training programs
could teach physicians how to present this model to patients
and implement it effectively. Because traditional continuing
medical education programs are ineffective at producing
behavioral change, more research is needed to develop effective
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training programs. Senior faculty and attendings should be
included in any such effort.
A second effort aimed at training physicians in the skills of
taper and discontinuation of benzodiazepines will likely require
a more large-scale, expensive, and multipronged effort. To be
effective, the program would need to convince physicians of the
threats to the health of the elderly involved in this practice and
provide some experience with specific counseling skills.
Difficulties in getting physicians to change their practices,
even when supported by recommendations, are considerable
and well-documented.
14,15 This study explicated primary care
physicians’ perspectives on reasons for not addressing the
chronic use of benzodiazepines among older patients and the
formidable challenges if they decided to do so. Such research
provides a more sympathetic perspective on the practicing
physician that can in turn lead to more engaging, persuasive
efforts to change their behavior.
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